Cavero, V.
Toyama, M.
Castro, H.
Couto, M. T.
Brandt, L.
Quayle, J.
Menezes, P. R.
Mohr, D. C.
Araya, R.
Miranda, J. J.
Diez-Canseco, F.
Funding for this research was provided by:
National Institute of Mental Health (1U19MH098780, 1U19MH098780, 1U19MH098780, 1U19MH098780, 1U19MH098780, 1U19MH098780, 1U19MH098780, 1U19MH098780, 1U19MH098780, 1U19MH098780, 1U19MH098780)
Article History
Received: 19 April 2022
Accepted: 17 May 2022
First Online: 3 June 2022
Declarations
:
: Approval was obtained from the ethics committees of the US National Institute of Mental Health Data and Safety Monitoring Board and local Ethics Committees in Brazil (Universidade de São Paulo) and Peru (Universidad Peruana Cayetano Heredia). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study.
: David C. Mohr, PhD has accepted honoraria and consulting fees from Otsuka Pharmaceuticals, Optum Behavioral Health, Centerstone Research Institute, and the One Mind Foundation, royalties from Oxford Press, and has an ownership interest in Adaptive Health, Inc. Funding for his time is on NIMH P50 MH119029. All other authors reported receipt of grants from NIMH (U19MH098780/3U 19MH098780-04S1) during the conduct of the study.